Introduction
Methods
Results
Conclusions
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of Preventive MedicineREFERENCES
HHS, NIH, National Institute on Drug Abuse. Research Report: Misuse of Prescription Drugs. www.drugabuse.gov/publications/research-reports/misuse-prescription-drugs/summary. Updated January 2018. Accessed June 3, 2018.
HHS, Food and Drug Administration, Center for Drug Evaluation and Research. Assessment of abuse potential of drugs—guidance for industry. www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm198650.pdf. Updated January 2018. Accessed June 4, 2018.
- Increasing deaths from opioid analgesics in the United States.Pharmacoepidemiol Drug Saf. 2006; 15: 618-627
- HHS Acting secretary declares public health emergency to address national opioid crisis [press release].(Published 2017 Updated April 24, 2018. Accessed December 16,)
HHS, Centers for Disease Control and Prevention (CDC), National Center for Health Statistics. Multiple Cause of Death 1999–2016 on CDC WONDER Online Database. http://wonder.cdc.gov/mcd-icd10.html. Updated December 2017. Accessed March 30, 2018.
HHS, NIH, National Institute on Drug Abuse. Opioid involvement in benzodiazepine overdose. www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates. Updated September 2017. Accessed March 30, 2018.
- Our other prescription drug problem.N Engl J Med. 2018; 378: 693-695
- Physician prescribing of opioids to patients at increased risk of overdose from benzodiazepine use in the United States.JAMA Psychiatry. 2018; 75: 623-630
- Trends in the concomitant prescribing of opioids and benzodiazepines, 2002–2014.Am J Prev Med. 2016; 51: 151-160
- Emergency department visits and overdose deaths from combined use of opioids and benzodiazepines.Am J Prev Med. 2015; 49: 493-501
- Vital signs: trends in emergency department visits for suspected opioid overdoses—United States, July 2016–September 2017.MMWR Morb Mortal Wkly Rep. 2018; 67: 279-285
- Evaluation and overview of the National Electronic Injury Surveillance System–Cooperative Adverse Drug Event Surveillance Project (NEISS-CADES).Med Care. 2007; 45: S96-S102
Schroeder T, Ault K. The NEISS sample (design and implementation) 1997 to present. www.cpsc.gov//PageFiles/106617/2001d011-6b6.pdf. Updated June 1, 2001. Accessed March 28, 2018.
U.S. Consumer Product Safety Commission. NEISS—The National Electronic Injury Surveillance System: a tool for researchers. www.cpsc.gov/PageFiles/106626/2000d015.pdf. Updated March 2000. Accessed October 1, 2018.
- Distinguishing public health research and public health nonresearch.(Published 2010 Updated July 31, 2018. Accessed December 16,)
- Things that work, things that don't work, and things that matter—including words.J Addict Med. 2015; 9: 429-430
- Language and addiction: choosing words wisely.Am J Public Health. 2013; 103: e1-e2
- Trends in medical use of opioids in the U.S., 2006–2016.Am J Prev Med. 2018; 54: 652-660
- Prescription opioid use, misuse, and use disorders in U.S. adults: 2015 National Survey on Drug Use and Health.Ann Intern Med. 2017; 167: 293-301
- Identifying injection drug users at risk of nonfatal overdose.Acad Emerg Med. 2007; 14: 616-623
- Opioid prescribing after nonfatal overdose and association with repeated overdose: a cohort study.Ann Intern Med. 2016; 164: 1-9
- Causes of death after nonfatal opioid overdose.JAMA Psychiatry. 2018; 75: 820-827
- Combatting opioid overdoses in Ohio: emergency department physicians’ prescribing patterns and perceptions of naloxone.J Gen Intern Med. 2018; 33: 608-609
HHS, Office of the Surgeon General. Surgeon General's advisory on naloxone and opioid overdose. www.surgeongeneral.gov/priorities/opioid-overdose-prevention/naloxone-advisory.html. Updated April 2018. Accessed May 1, 2018.
- CDC guideline for prescribing opioids for chronic pain – United States, 2016.MMWR Recomm Rep. 2016; 65: 1-49
- A pilot randomized clinical trial of an intervention to reduce overdose risk behaviors among emergency department patients at risk for prescription opioid overdose.Drug Alcohol Depend. 2016; 163: 40-47
- Behavioral intervention to reduce opioid overdose among high-risk persons with opioid use disorder: a pilot randomized controlled trial.PLoS One. 2017; 12e0183354.
- Emergency department-initiated buprenorphine for opioid dependence with continuation in primary care: outcomes during and after intervention.J Gen Intern Med. 2017; 32: 660-666
- Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study.Ann Intern Med. 2018; 169: 137-145
- Overdose prevention through medical treatment of opioid use disorders.Ann Intern Med. 2018; 169: 190-192
HHS, Food and Drug Administration. FDA's opioid analgesic REMS education blueprint for health care providers involved in the treatment and monitoring of patients with pain (revised FDA blueprint). www.regulations.gov/contentStreamer?documentId=FDA-2017-D-2497-0683&attachmentNumber=1&contentType=pdf. Updated January 2018. Accessed May 3, 2018.
HHS, Substance Abuse and Mental Health Services Administration and Health Resources and Services Administration. Drug & alcohol use screening tools. www.integration.samhsa.gov/clinical-practice/screening-tools#drugs. Updated 2018. Accessed May 11, 2018.
- Treatment of benzodiazepine dependence.N Engl J Med. 2017; 376: 1147-1157
HHS, Substance Abuse and Mental Health Services Administration and Health Resources and Services Administration. Safe & effective use of benzodiazepines in clinical practice. www.integration.samhsa.gov/about-us/Benzodiazepines_Presentation.pdf. Updated May 2017. Accessed May 16, 2018.
- Misuse and abuse of pregabalin and gabapentin: cause for concern?.CNS Drugs. 2014; 28: 491-496
- Abuse and misuse of pregabalin and gabapentin.Drugs. 2017; 77: 403-426
- The FDA and the next wave of drug abuse: proactive pharmacovigilance.N Engl J Med. 2018; 379: 205-207
Gottlieb S. Emerging issues of misuse and abuse of OTC loperamide challenge FDA to address a new turn in the opioid addiction crisis, while maintaining access for patients. https://blogs.fda.gov/fdavoice/index.php/2018/05/emerging-issues-of-misuse-and-abuse-of-otc-loperamide-challenge-fda-to-address-a-new-turn-in-the-opioid-addiction-crisis-while-maintaining-access-for-patients/. Updated May 2018. Accessed May 13, 2018.
HHS, Food and Drug Administration. FDA Drug Safety Communication: FDA limits packaging for anti-diarrhea medicine loperamide (Imodium) to encourage safe use. www.fda.gov/Drugs/DrugSafety/ucm594232.htm. Updated January 2018. Accessed May 14, 2018.
- Pediatric ADHD medication exposures reported to U.S. poison control centers.Pediatrics. 2018; 141e20173872.
- Suicide: a silent contributor to opioid-overdose deaths.N Engl J Med. 2018; 378: 1567-1569
- Opioid prescriptions for chronic pain and overdose: a cohort study.Ann Intern Med. 2010; 152: 85-92
- Classifying nonsuicidal overdoses: nonsuicidal self-injury, suicide attempts, or neither?.Psychiatry Res. 2016; 244: 235-242
